About Foamix

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
 
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne,FMX 103 for the treatment of rosacea,  FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
 
Read More

Minocycline Foam

We are developing a topical formulation of minocycline utilizing our proprietary foam technology platform. Our development program consists of three potential indications that we are pursuing: moderate-to-severe acne, impetigo, and rosacea. 
  
Our phase II results of minocycline foam 4%, applied once-daily, for the treatment of moderate-to-severe acne, showed greater than a 70% reduction in inflammatory acne lesions. We intend to commence Phase III trials for minocycline foam 4% in the United States in 2016

 

Read More

Recent News

Nov 28

Foamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea 

Read more...
Nov 28

Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101 

Read more...
Nov 15
Foamix Reports Third Quarter 2016 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, November 16, 2016 at 8:30am Eastern / 5:30am Pacific 
Read more...